Navigation Links
Cambrex Reports Third Quarter 2013 Financial Results
Date:11/1/2013

EAST RUTHERFORD, N.J., Nov. 1, 2013 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2013.

Highlights

  • Third quarter sales increased to $78.0 million from $59.8 million in the third quarter of 2012. 
  • Third quarter EBITDA increased to $17.0 million compared to $9.6 million in the same period last year (see table at the end of this release). 
  • Debt, net of cash was $76.0 million at the end of the third quarter, an increase of $8.5 million during the quarter. 
  • 2013 full year sales and EBITDA guidance ranges tightened, increased lower end of ranges (see Financial Expectations section below).
  • "We are very pleased with our strong third quarter financial results and narrowed our full year guidance range, increasing the lower end of the range for both sales and EBITDA, reflecting our confidence in expected full year results," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.  "Our Charles City, Iowa facility began shipping commercial launch quantities of an API for a key new product candidate and we are currently on schedule to ship higher volumes of this new API than was previously expected for 2013.  As we've indicated in recent quarters, we continue to see strong demand for late stage custom development products."

    Third Quarter 2013 Operating Results
    Sales of $78.0 million were 30.3% higher compared to the same period last year, including the favorable impact of foreign exchange of 1.8%.  The increase was primarily due to higher sales of a large phase 3 product and certain branded active pharmaceutical ingredients ("APIs"), partially offset by lower sales of generic APIs and products utilizing the Company's drug delivery technology.Gross margins increased to 32.0% from 31.0% compared to the same
    '/>"/>

    SOURCE Cambrex Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
    2. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
    3. Cambrex Reports Third Quarter 2012 Financial Results
    4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
    5. Cambrex Announces Significant New Supply Agreement
    6. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
    7. Cambrex Reports First Quarter 2012 Results
    8. IRIDEX Reports 2013 Third Quarter Results
    9. Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
    10. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy
    11. Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... with AbbVie (NYSE: ABBV ) to develop and ... ENHANZE ™ platform. Under ... an initial $23 million payment, followed by milestone ... up to nine collaboration targets. These payments are ...
    (Date:6/3/2015)... Calif. , June 3, 2015  Flow ... sector around the globe and keeping track of ... this competitive market. In particular, ensuring user-friendliness, fluorescence ... sensitivity are the most important factors influencing end-user ... consumer base. New analysis from Frost ...
    (Date:6/3/2015)... , June 3, 2015  (AHIP Institute Booth ... information network, will be providing a wide range of ... future during the America,s Health Insurance Plan,s (AHIP,s) ... Tenn. Availity released a ... problem of waste and missed opportunities." The report ...
    Breaking Medicine Technology:Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4Availity to Share Insights, Tools and Strategies at AHIP 2015 to Enable Health Plans to Achieve Long-term, Sustainable Success in an Evolving Value-based Environment 2Availity to Share Insights, Tools and Strategies at AHIP 2015 to Enable Health Plans to Achieve Long-term, Sustainable Success in an Evolving Value-based Environment 3
    ... premier Canadian pharmacy intermediary since 2002, reveals the top ... a Canada pharmacy . 1. Low Prices - ... less than the U.S. price and SaveRxCanada.com has been negotiating the ... – Many patients are elderly and find it difficult to get ...
    ... 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... medical dressings, medical disposables and non-woven fabric made from ... it will release financial results for its second quarter ... Medical,s senior management will host a conference call to ...
    Cached Medicine Technology:Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2Winner Medical Group Inc. to Host Second Quarter 2011 Earning Conference Call on Wednesday, May 11, 2011 at 08:30 a.m. EDT 2
    (Date:6/3/2015)... Loma Linda University Health and Adventist Health ... Memorial Hospital (SGMH). The SGMH board voted unanimously to ... “Loma Linda University Health has been serving the Pass ... officer, Loma Linda University Medical Center. “We are thrilled ... this community.” , Under the proposed affiliation, Loma ...
    (Date:6/3/2015)... The Canton Group, a leading web and ... today that Tim Dodge has joined the company as ... Canton Group as it implements an ambitious growth ... Tim is a tech industry veteran who has developed ... companies. Before joining The Canton Group, Tim was Vice ...
    (Date:6/3/2015)... On June 22, 2015, Medicare will begin denying coverage ... that it has reimbursed since 2009. , Payment denial ... the 49 million Medicare beneficiaries in the U.S. who are ... Sadly, if it became a standard of care, this testing ... an individual’s genetic information to tailor treatment, is by all ...
    (Date:6/3/2015)... 2015 Horizon Blue Cross Blue Shield of ... one of the nation’s top employers for diverse managers and ... its national list of Best Places for Diverse Managers and ... 1 Regional Company. This is the sixth consecutive year ... for its diverse workplace policies and programs. , Companies are ...
    (Date:6/3/2015)... 03, 2015 A group of nine ... with a Global Inspire Award at DIA’s upcoming Annual ... outstanding volunteers for their leadership, level of excellence, and ... , The recipients of the Author(s) of the Year ... whose article has made a significant impact in advancing ...
    Breaking Medicine News(10 mins):Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4
    ... the first long-term randomized trial of a chemopreventive agent for ... cancer in the drug-treated group may be attributable to shrinkage ... The study of the Prostate Cancer Prevention Trial, led by ... Gann, is published in the Sept. 12 issue of the ...
    ... Providers, SEATTLE, Sept. 12 , News Facts -- ... concerns and interests to the 2008 presidential candidates ... online physician community. -- The initiative is enabling U.S. licensed ... via individual web-based videos. Experts from a ...
    ... Wrinkles, HIGHLANDS, N.J., Sept. 12 Fifty really ... men in their 40s and 50s look better than,their ... can look incredibly sexy at any age. So ... keep the,attention of handsome himbos and beautiful babes? Biocap, ...
    ... Corporation,(Nasdaq: KNSY ) today announced that it will ... 30, 2007 at 7:00 A.M. Eastern Time on,Friday, October ... be hosting a teleconference,discussing the earnings results on Friday, ... participate in the teleconference call, dial 1-651-291-5254. The,teleconference call ...
    ... billion dollars. , But an unhealthy kidney costs moreabout ... associate professor in the division of nephrology and hypertension ... about $17 billion a year to care for patients ... currently over 320,000 people undergoing hemodialysis in the United ...
    ... Centers Head and Neck Cancer Center is teaming up ... cancer. The clinical alliance between Mount Sinai and ENT ... allergy and audiology practice in the tri-state area, together ... quality care, cancer screening and advanced surgical options for ...
    Cached Medicine News:Health News:Shrinkage of prostate led to overestimation of cancer risk in trial 2Health News:U.S. Physicians Question Presidential Candidates 2Health News:Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser 2Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Clinical trials present better alternatives for dialysis patients 2Health News:Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer 2
    ... Constructed of optical steel ... electro-plate. Comes with custom ... that create a seal ... for increased scatter radiation ...
    ... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
    ... eye protection Properly manufactured radiation protective ... radiation. Our high quality frames and materials ... minimized weight. Our lenses are made of ... all industry standards. Most Pulse Glasses are ...
    ... Both lenses and frames are designed with the ... Our lenses are Schott RS-520 (also called SF-6) ... glass. These lenses meet standards, as set for ... correction. ,While our eyewear is protecting your ...
    Medicine Products: